课题基金 / 基金详情

项目摘要

项目成果

Jing Li的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Pharmacology Core's mission is to provide state-of-the-art technology and expertise in bioanalysis, pharmacokinetics, and pharmacogenetics for evaluation of critical pharmacological endpoints in preclinical and eariy phase clinical studies. Two services, including pharmacokinetic/pharmacodynamic (PK/PD) sample processing and distribution service and bioanalysis service, have been provided since 2004. The PK/PD sample processing and distribution service provides support for clinical trials, including specimen transport, accountability, processing, storage, and distribution, in compliance with applicable Standard Operating Procedures (SOPs), IRB-approved protocols, and regulatory requirements. The bioanalysis service provides quantitative measurement of drugs and metabolites in biological samples (e.g., blood, plasma, serum, urine, or tissue samples) using high-performance liquid chromatography (HPLC) coupled with ultraviolet or fluorescence detection or tandem mass spectrometer detection (LC-MS/MS). In addition, three new service lines were recently developed in order to provide KCI investigators with comprehensive pharmacology support. These new services include: 1) bioanalytical methods development and validation service that includes evaluating all procedures for accuracy, precision, selectivity, sensitivity, reproducibility and stability of a particular HPLC or LC-MS/MS method; 2) pharmacokinetic data analysis and modeling service that provides assistance in preclinical and clinical pharmacokinetic experimental design and protocol development as well as analysis and interpretation of pharmacokinetic data using traditional or population pharmacokinetic modeling approaches; and 3) pharmacogenetic analysis is a collaborative service with the Genomics Core that focuses on employing a candidate gene approach to examine the associations between common single nucleotide polymorphisms (SNPs) in selected genes (such as genes encoding drug metabolizing enzymes, transporters, or target receptors/enzymes) and PK parameters, PD effects, or clinical outcome (efficacy or toxicity) of clinical investigational anticancer agents. The Core is equipped with stateof- the-art analytical instruments such as LC-MS/MS. Available pharmacokinetic analysis software includes WinNonlin version 5.2 and NONMEM version 6. The laboratory is centrally located with convenient access forthe KCI investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AIDen: An AI-empowered detection and diagnosis system for jaw lesions using CBCT
  • 批准号:
    10383494
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2022
  • 负责人:
    Jing Li
  • 依托单位:
Physiologically Based Pharmacokinetic Modeling of Drug Penetration into the Human Brain and Brain Tumors
  • 批准号:
    10674753
  • 项目类别:
  • 资助金额:
    $36.94万
  • 财政年份:
    2021
  • 负责人:
    Jing Li
  • 依托单位:
Physiologically Based Pharmacokinetic Modeling of Drug Penetration into the Human Brain and Brain Tumors
  • 批准号:
    10459595
  • 项目类别:
  • 资助金额:
    $37.32万
  • 财政年份:
    2021
  • 负责人:
    Jing Li
  • 依托单位:
Physiologically Based Pharmacokinetic Modeling of Drug Penetration into the Human Brain and Brain Tumors
  • 批准号:
    10298016
  • 项目类别:
  • 资助金额:
    $39.43万
  • 财政年份:
    2021
  • 负责人:
    Jing Li
  • 依托单位:
海外基金